IGFBP2 and IGFBP3 protein expressions in human breast cancer: Association with hormonal factors and obesity

Clinical Cancer Research

Volumn 16, Issue 3, 2010, Pages 1025-1032

  Probst Hensch, Nicole M ^d   Steiner, Julia H B ^a   Schraml, Peter ^b   Varga, Zsuzsanna ^b   Zürrer Härdi, Ursina ^b   Storz, Martina ^b   Korol, Dimitri ^a   Fehr, Mathias K ^b   Fink, Daniel ^b   Pestalozzi, Bernhard C ^b   Lütolf, Urs M ^b   Theurillat, Jean Philippe ^b   Moch, Holger ^b,c  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c Competence Center of Systems Physiology and Metabolic Disease ^*  (Switzerland)

^d SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; BREAST CANCER; CANCER GRADING; CANCER STAGING; CONFIDENCE INTERVAL; FEMALE; GENE AMPLIFICATION; HAZARD RATIO; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OBESITY; ONCOGENE NEU; OVERALL SURVIVAL; POSTMENOPAUSE; PREDICTION; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY;

AGED; BREAST NEOPLASMS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED; OBESITY; PROGESTERONE; RECEPTORS, ESTROGEN;

EID: 76049128733     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0957     Document Type: Article

References (50)

1. Majed B, Moreau T, Senouci K, Salmon RJ, Fourquet A, Asselain B. Is obesity an independent prognosis factor in woman breast cancer? Breast Cancer Res Treat 2008;111:329-42.
2. Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin- IGF axis. Trends Endocrinol Metab 2006a;17: 328-36.
3. Sachdev D, Yee D. Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer. J Mammary Gland Biol Neoplasia 2006;11:27-39.
4. Bonnette SG, Hadsell DL. Targeted disruption of the IGF receptor gene decreases cellular proliferation in mammary terminal end buds. Endocrinology 2001;142:4937-45.
5. Hovey RC, Harris J, Hadsell DL, Lee AV, Ormandy CJ, Vonderhaar BK. Local I nsulin-like growth factor-II mediates prolactin-induced mammary gland development. Mol Endocrinol 2003;17:460-71.
6. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002;23:824-54.
7. Wu Y, Cui K, Miyoshi K, et al. Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res 2003;63:4384-8.
8. Patel AV, Cheng I, Canzian F, et al. IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PloS One 2008;3:e2578.
9. So AI, Levitt RJ, Eigl B, et al. Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer. Clin Cancer Res 2008;14:6944-54.
10. Yee D, Sharma J, Hilsenbeck SG. Prognostic significance of insulin-like growth factor-binding protein expression in axillary lymph nodenegative breast cancer. J Natl Cancer Inst 1994;86:1785-9.
11. Wang H, Arun BK, Wang H, et al. IGFBP-2 and IGFBP-5 overexpression correlate with the lymph node metastasis in T1 breast carcinomas. Breast J 2008;14:261-7.
12. Clemmons DR, Camacho-Hubner C, Coronado E, Osborne CK. Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: correlation with estrogen receptor status. Endocrinology 1990;127:2679-86.
13. Haffner MC, Petridou B, Peyrat JP, et al. Favorable prognostic value of SOCS2 and IGF-I in breast cancer. BMC Cancer 2007;7:136.
14. Shin A, Ren Z, Shu X-O, Cai Q, Gao Y-T, Zheng W. Expression patterns of insulin- like growth factor 1 (IGF-I) and its receptor in mammary tissues and their associations with breast cancer survival. Breast Cancer Res Treat 2007a;105:55-61.
15. Chong YM, Williams SL, Elkak A, Sharma AK, Mokbel K. Insulin-like growth factor 1 (IGF-1) and its receptor mRNA levels in breast cancer and adjacent non-neoplastic tissue. Anticancer Res 2006;26: 167-73.
16. Happerfield LC, Miles DW, Barnes DM, Thomsen LL, Smith P, Hanby A. The localization of the insulin-like growth factor receptor 1 (IGFR-1) in benign and malignant breast tissue. J Pathol 1997;183:412-7.
17. Mizukami Y, Nonomura A, Yamada T, et al. Immunohistochemical demonstration of growth factors, TGF-α, TGF-β, IGF-I and neu oncogene product in benign and malignant breast tissues. Anticancer Res 1990;10:1115-26.
18. Nardon E, Buda I, Stanta G, Buratti E, Fonda M, Cattin L. Insulin-like growth factor system gene expression in women with type 2 diabetes and breast cancer. J Clin Pathol 2003;56:599-604.
19. Papa V, Gliozzo B, Clark GM, et al. Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res 1993;53:3736-40.
20. Schnarr B, Strunz K, Ohsam J, Benner A, Wacker J, Mayer D. Down-regulation of insulin-like g growth factor-I receptor and insulin receptor substrate-1 expression in advancer human breast cancer. Int J Cancer 2000;89:506-13.
21. Voskuil DW, Bosma A, Vrieling A, Rookus MA, van't Veer LJ. Insulin-like growth factor (IGF)-system mRNA quantities in normal and tumor breast tissue of women with sporadic and familial breast cancer risk. Breast Cancer Res Treat 2004;84:225-33.
22. Ellis IO, Schnitt SJ, Sastre-Garau X, et al. Pathology and Genetics Tumours of the Breast and Female Genital Organs. IARC WHO Classification of Tumours, No 4 Edition. IARC Press; 2003.
23. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
24. Torhorst J, Bucher C, Kononen J, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 2001; 159:2249-56.
25. Theurillat J-P, Zürrer-Härdi U, Varga Z, et al. NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapy. Cancer Immunol Immunother 2007;56:1723-31.
26. Helle SI. The insulin-like growth factor system in advanced breast cancer. Best Pract Clin Endocrinol Metab 2004;18:67-79, Review.
27. Eppler E, Zapf J, Bailer N, Falkmer UG, Falkmer S, Reinecke M. IGF-I in human breast cancer: low differentiation stage is associated wtih decreased IGF-I content. Eur J Endocrinol 2002;146:813-21.
28. Hamelers ICH, Steenbergh PH. Interactions between estrogen and insulin-like growth factor signalling pathways in human breast tumor cells. Endocr Relat Cancer 2003;10:331-45.
29. Koda M, Przystup W, Jarzabek K, et al. Expression of insulin-like growth factor-I-receptor, estrogen receptor α, Bcl- 2 and Bax proteins in human breast cancer. Oncol Rep 2005;14:93-8.
30. Vestey SB, Perks CM, Sen C, Calder CJ, Holly JMP, Winters ZE. Immunohistochemical expression of insulin-like growth factor binding protein-3 in invasive breast cancer and ductal carcinoma in situ: implications for clinicopathology and patient outcome. Breast Cancer Res 2005;7:R119-29.
31. Yu H, Levesque A, Khosravi MJ, Papanastasiou-Diamandi A, Clark GM, Diamandis EP. Insulin-like growth factor-binding protein-3 and breast cancer survival. Int J Cancer 1998;79:624-8.
32. Yu H, Levesque MA, Khosravi MJ, Papanastasiou-Diamandi A, Clark GM, Diamandis EP. Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer. Br J Cancer 1996;74:1242-7.
33. Rocha RL, Hilsenbeck SG, Jackson JG, Lee AV, Figueroa JA, Yee D. Correlation of insulin-like growth factor-binding protein expression in primary breast cancer tissues: detection of higher levels in tumors with poor prognostic features. J Natl Cancer Inst 1996;88: 601-6.
34. Shivakumar S, Prabhakar BT, Jahashree K, Rajan MGR, Salimath BP. Evaluation of serum vascular endothelial growth factor (VEGF) and microvessel density (MVD) as prognostic indicators in breast carcinoma. J Cancer Res Clin Oncol 2009;135:627-36.
35. Schmid MC, Bisoffi M, Wetterwald A, et al. Insulin-like growth factor binding protein-3 is overexpressed in endothelial cells of mouse breast tumor vessels. Int J Cancer 2003;103:577-86.
36. Ren Z, Shin A, Cai Q, Shu X-O, Gao Y-T, Zheng W. IGFBP3 mRNA expression in benign and malignant breast tumors. Breast Cancer Res 2007;9:R2.
37. Guo S, Russo IH, Russo J. Difference in gene expression profile in breast epithelial cells from women with different reproductive history. Int J Oncol 2003;23:933-41.
38. Goodwin PJ, Ennis M, Pritchard KI, et al. Insulin- like growth factor binding protein 1 and 3 and breast cancer outcomes. Breast Cancer Res Treat 2002;74:65-76.
39. Hoeflich A, Reisinger R, Lahm H, et al. Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter? Cancer Res 2001;61:8601-10.
40. Renehan AG, Jones J, Potten CS, Shalet SM, O'Dwyer ST. Elevated serum insulin- like growth factor (IGF)-II and IGF-binding protein-2 in patients with colorectal cancer. Br J Cancer 2000;83:1344-50.
41. Baron-Hay S, Boyle F, Ferrier A, Scott C. Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer. Clin Cancer Res 2004;10:1796-806.
42. Lin Y, Jiang T, Zhou K, et al. Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas. Neuro-oncol 2009;11: 468-76.
43. Mehrian-Shai R, Chen CD, Shi T, et al. Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci U S A 2007;104:5563-8.
44. Frommer KW, Reichenmiller K, Schutt BS, et al. IGF-independent effects of IGFBP-2 on the human breast cancer cell line Hs578T. J Mol Endocrinol 2006;37:13-23.
45. Pereira JJ, Meyer T, Docherty SE, et al. Biomolecular interaction of insulin-like growth factor (IGF) binding protein-2 with αvβ3 negatively modulates IGF-I mediated migration and tumor growth. Cancer Res 2004;64:977-84.
46. Zhang CC, Kama M, Iizuka S, Huynh HD, Lodish HF. Angiopoietin-like 5 adn IGFBP2 stimulate ex vivo expansion of human cord blood haematopoietic stem cells as assayed by NOD/SCID transplantation. Blood 2008;111:3415-23.
47. Wheatcroft SB, Kearney MT, Shah AM, et al. IGF- binding protein-2 protects against the development of obesity and insulin resistance. Diabetes 2007;56:285-94.
48. Carmichael AR. Obesity and prognosis of breast cancer. Obes Rev 2006;7:333-40.
49. Ahmed RL, Thomas W, Schmitz KH. Interactions between insulin, body fat, and insulin-like growth factor axis proteins. Cancer Epidemiol Biomarkers Prev 2007;16:593-7.
50. Wheatcroft SB, Kerney MT. IGF-dependent and IGF-independent actions of IGF- binding protein-1 and -2: impications for metabolic homeostasis. Trends Endocrinol Metab 2009;20:153-62.